WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?

Phase 4

Terminated

Conditions: Pain

Interventions: Drug: Placebo
Drug: Acetaminophen

First Posted Date: 2014-07-03

Last Posted Date: 2018-09-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 33

Registration Number: NCT02181387

Locations: 🇺🇸
Forsyth Medical Center, Winston-Salem, North Carolina, United States

Sphenopalatine Ganglion Block for Post-Dural Puncture Headache

Not Applicable

Withdrawn

Conditions: Postdural Puncture Headache
Sphenopalatine Ganglion Block

Interventions: Drug: placebo
Drug: bupivacaine

First Posted Date: 2014-07-03

Last Posted Date: 2017-11-08

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02181205

Locations: 🇺🇸
Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States

Cutaneous Lupus Medication Experience Study

Active, not recruiting

Conditions: Cutaneous Lupus

Interventions: Drug: fluocinonide 0.05% cream

First Posted Date: 2014-06-26

Last Posted Date: 2024-12-04

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 11

Registration Number: NCT02176148

Locations: 🇺🇸
Wake Forest University School of Medicine - Department of Dermatology, Winston-Salem, North Carolina, United States

KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer

Not Applicable

Withdrawn

Conditions: Ductal Breast Carcinoma in Situ
Skin Reactions Secondary to Radiation Therapy
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Procedure: dermatologic complications management/prevention
Other: questionnaire administration

First Posted Date: 2014-06-20

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02168179

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: B-cell Adult Acute Lymphoblastic Leukemia
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Mycosis Fungoides/Sezary Syndrome
Intraocular Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride
Biological: rituximab
Other: laboratory biomarker analysis

First Posted Date: 2014-06-20

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 1

Registration Number: NCT02168907

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Adult Lymphocyte Predominant Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
T-cell Large Granular Lymphocyte Leukemia
Adult Nasal Type Extranodal NK/T-cell Lymphoma
T-cell Adult Acute Lymphoblastic Leukemia
Noncutaneous Extranodal Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride

First Posted Date: 2014-06-20

Last Posted Date: 2024-02-13

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 16

Registration Number: NCT02168140

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IIIA Melanoma
Stage IIIB Melanoma
Unspecified Adult Solid Tumor, Protocol Specific
Stage III Renal Cell Cancer
Recurrent Pancreatic Cancer
Recurrent Renal Cell Cancer
Stage IIIC Melanoma
Recurrent Melanoma
Stage IV Pancreatic Cancer
Stage IV Renal Cell Cancer